1 / 20

PROactive

PROactive. Physical Activity as a Crucial Patient Reported Outcome in COPD Thierry.troosters@med.kuleuven.be info@proactivecopd.be. What patients need What Europe needs. Chronic Obstructive Pulmonary Disease is a disease with increasing prevalence. Prevalence in 40+ population.

jonco
Télécharger la présentation

PROactive

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PROactive Physical Activity as a Crucial Patient ReportedOutcome in COPD Thierry.troosters@med.kuleuven.be info@proactivecopd.be

  2. What patients need What Europe needs • Chronic Obstructive Pulmonary Disease is a disease with increasing prevalence Prevalence in 40+ population Prevalence (%) Buist et al Lancet 2007

  3. What patients need What Europe needs • Chronic Obstructive Pulmonary Disease is a disease with increasing prevalence • Treatment based on Prevention, Pharmacotherapy, Non-Pharmacological interventions (www.goldcopd.com)

  4. What patients need What Europe needs • Chronic Obstructive Pulmonary Disease is a disease with increasing prevalence • Treatment based on Prevention, Pharmacotherapy, Non-Pharmacological interventions (www.goldcopd.com) • Problems for patients: • Airflow obstruction, Symptoms, Exacerbations, reduction in physical activity • ‘systemic consequences’

  5. What patients need What Europe needs Pathology What the disease means to the patient Troosters Respir Medicine 2010 Watz AJRCCM 2008

  6. What patients need What Europe needs Classical outcomes Lung function CT-scan (Bio-markers) Pathology Classical outcomes Exercise capacity Patient Reported Outcomes Few are available What the disease means to the patient

  7. What patients need What Europe needs • What is the effect of our interventions on outcomes that are relevant to the patients suffering from COPD? Criteria for a modern Patient Reported Outcome: Meaningful to clinicians Responsive to clinically relevant treatment effects Understandable to patients Acceptable to Regulatory Authorities

  8. What we will do about it • PROactive will develop Patient Reported Outcome tools that capture the impact of COPD and our treatments on physical activity • Step 1: What are according to the patients relevant aspects of physical activity? • What can I do • How many symptoms do I experience • Difference on ‘a bad day’ • Problems by not being able to cary out expected tasks

  9. What we will do about it • Step 1: What are according to the patients relevant aspects of physical activity? Information directly from patients Information from literature Dimensions & Items Information from experts

  10. What we will do about it • Step 1: What are according to the patients relevant aspects of physical activity? • Step 2: Integrate this in a new tool, using modern patient friendly technology. Activity monitor E-PRO tool for other dimensions

  11. What we will do about it • Step 1: What are according to the patients relevant aspects of physical activity? • Step 2: Integrate this in a new tool, using modern patient friendly technology. • Step 3: Validate the new PRO’s in the European population, taking into account culturaly sensitive aspects.

  12. Innovative approach • Start from the patient’s perspective, as current regulatory guidance advocates • Integrate objective assessment and Patient report to cover a domain as difficult as Physical Activity Symptoms / PA Time (days)

  13. Expected outcome • Patient Reported Outcome tools integrating monitors and questionnaires for daily use and clinical visits in COPD • A blue print for other chronic diseases where PA is equally important.

  14. Expected benefit to patients • Tools available to monitor the progression and improvement in an extremely relevant domain. • A new and integrated outcome may open a window of opportunities for the acceptance of new therapies or combinations. • These combinations may integrate pharmacological and non-pharmacological interventions.

  15. Added value of the consortium EFPIA members • Expertise in PRO development • Ongoing clinical trials allowing validation • Expertise integrating technology • Multicenter studies • Powerful Project management • Network of clinical experts across EU and the world • Established contact with regulators

  16. Added value of the consortium Patient / Scientific organizations Academic partners UMCG Small Medium Enterprise

  17. Results/achievements so far • Literature reviews on 5 topics: • What is the relation between PA and other outcomes • What questionnaires and items are available • What activity monitors are available • Qualitative studies in COPD: is PA important • What dimensions are relevant

  18. Results/achievements so far • Literature reviews on 5 topics • In 3 centers individual patient interviews and Focus groups are completed • In 4 centers 7 activity monitors are validated

  19. Time and money Financing • IMI funding: 6.767.597 of a cost of 8.584.809 € • EFPIA contribution, mainly in kind: 8.163.949 € • Total project cost: 16.748.758 € Timing: • Starting date: September 2009 • Duration: 5 years

  20. Further information info@proactivecopd.com C.Brindicci@chiesigroup.com (coordinator) Thierry.troosters@med.kuleuven.be (Scientific leader) www.proactivecopd.com www.imi.europa.eu

More Related